Buranakitjaroen Peera, Deerochanawong Chaicharn, Bunnag Pongamorn
Division of Hypertension, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Rd, Bangkoknoi, Bangkok 10700, Thailand.
J Med Assoc Thai. 2005 Nov;88(11):1624-9.
Microalbuminuria represents the earliest clinical evidence of diabetic nephropathy, and is a marker of increased cardiovascular (CV) morbidity and mortality.
This analysis of Thai data from the Microalbuminuria Prevalence Study (MAPS) assessed the prevalence of macroalbuminuria and microalbuminuria in hypertensive patients with type 2 diabetes.
Cross-sectional clinic-based epidemiological study.
A total of 100 patients were enrolled, of which 97 patients constituted the per-protocol population (patients with bacteriuria and haematuria were excluded). Patients attended one study visit with no follow-up.
Overall, the prevalence of diabetic kidney disease was high, with macroalbuminuria contributing 13.4% [9.9-16.9; 95% confidence interval (CI)] and microalbuminuria contributing 43.3% [38.3-48.3; 95%CI].
Annual screening for microalbuminuria is recommended for all patients with type 2 diabetes, as early treatment is critical for reducing CV risks. Clinical studies have shown that renin-angiotensin system inhibitors can slow the progression of diabetic nephropathy.
微量白蛋白尿是糖尿病肾病最早的临床证据，也是心血管（CV）发病率和死亡率增加的标志物。
这项对微量白蛋白尿患病率研究（MAPS）中泰国数据的分析评估了2型糖尿病高血压患者中大量白蛋白尿和微量白蛋白尿的患病率。
基于门诊的横断面流行病学研究。
共纳入100例患者，其中97例患者构成符合方案人群（排除有菌尿和血尿的患者）。患者仅参加一次研究访视，无随访。
总体而言，糖尿病肾病的患病率较高，大量白蛋白尿占13.4%[9.9 - 16.9；95%置信区间（CI）]，微量白蛋白尿占43.3%[38.3 - 48.3；95%CI]。
建议对所有2型糖尿病患者每年进行微量白蛋白尿筛查，因为早期治疗对于降低CV风险至关重要。临床研究表明，肾素 - 血管紧张素系统抑制剂可减缓糖尿病肾病的进展。
